CAG
SRNE

Csenge Advisory Group’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Csenge Advisory Group’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-51,456
Closed -$45.6K – 651
2022
Q4 		$45.6K Hold
51,456
– – ﹤0.01% 584
2022
Q3 		$81K Hold
51,456
– – 0.01% 591
2022
Q2 		$103K Buy
+51,456
New +$89K 0.01% 557

Other funds holding SRNE

PP
Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return
LCM
Lattice Capital Management Kirkland, Washington $49.5M AUM 28.58% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return
GA
GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return
HFRG
Houlihan Financial Resource Group Ashburn, Virginia $281M AUM 17.68% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
GBWM
Granite Bay Wealth Management Portsmouth, New Hampshire $1.09B AUM 22.93% 1-Year Est. Return

Csenge Advisory Group's SRNE Position: Q1 2023 in Review

Csenge Advisory Group sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 51,456 shares — an estimated $45.6K sold.

Csenge Advisory Group first reported a position in SRNE in Q2 2022 and held it in 3 quarters. The position peaked at $103K in Q2 2022. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

  • Csenge Advisory Group reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • Csenge Advisory Group sold 51,456 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $45.6K.
  • Csenge Advisory Group first reported a position in Sorrento Therapeutics, Inc. in Q2 2022 and held it in 3 quarters.
  • Csenge Advisory Group's Sorrento Therapeutics, Inc. position peaked at $103K in Q2 2022.
  • 34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on Csenge Advisory Group's 13F filing for Q1 2023, filed 1 May 2023.